Asymptomatic until fracture occurs.
Diagnosis based on history of prior fragility fracture or low bone-mass density, which is defined as a T-score <-2.5.
Screening is based on individual risk factors, including female gender, maternal history of fragility fracture/osteoporosis, older age, low body mass index (<20-25 kg/m^2), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease.
Fall prevention is first-line therapy.
Bisphosphonates are first-line pharmacologic therapy for postmenopausal women and men.
In postmenopausal women, estrogen is considered only for those at high risk for whom nonestrogen medications are inappropriate.
CXR showing marked deformity and volume loss of bony thorax in a patient with osteoporosis
BMJ Case Reports 2009; doi:10.1136/bcr.07.2008.0359. Copyright ©BMJ publishing group 2010